X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MBN 101 (Pravibismane) is a small molecule antibacterial agent which is being evaluated in preclinical trials for the treatment of non-tuberculous mycobacterial (NTM) infections.
Lead Product(s): Pravibismane
Therapeutic Area: Infections and Infectious Diseases Product Name: MBN-101
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2024
Details:
MBN-101 (inhaled pravibismane) has received QIDP, Fast Track and Orphan drug designation from the USFDA for the treatment of pulmonary infections in patients with cystic fibrosis. Microbion has successfully completed non-clinical studies for the inhaled pravibismane program.
Lead Product(s): Pravibismane
Therapeutic Area: Infections and Infectious Diseases Product Name: MBN-101
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023
Details:
MBN-101 (pravibismane) is the first in a new class of anti-infective drugs demonstrating broad-spectrum potency against a wide range of multidrug-resistant bacteria, and biofilms ubiquitous in DFU infections.
Lead Product(s): Pravibismane
Therapeutic Area: Podiatry Product Name: MBN-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2023
Details:
MBN-101 (pravibismane) is first new class of anti-infective drugs with novel MOA, rapidly reduces bacterial ATP production in both planktonic and biofilm bacterial populations, thereby halting global bacterial cellular metabolism.
Lead Product(s): Pravibismane
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: MBN-101
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
MBN-101 has been granted Qualified Infectious Disease Product (QIDP) designation and Fast Track designation by the US FDA for: (1) adjunctive treatment of moderate and severe diabetic foot ulcer infection; and (2) treatment of post-surgical orthopedic implant infections.
Lead Product(s): Pravibismane
Therapeutic Area: Infections and Infectious Diseases Product Name: MBN-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Details:
Pravibismane (MBN-101) shuts down bacterial ATP production thereby halting global bacterial cellular metabolism. Pravibismane exhibits broad-spectrum, potent in vitro activity against pathogens and their biofilms including MRSA, CRE, and multidrug resistant P. aeruginosa.
Lead Product(s): Pravibismane
Therapeutic Area: Infections and Infectious Diseases Product Name: MBN-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2022
Details:
Pravibismane (MBN-101), is the first in a new class of anti-infective drugs structurally unrelated to other clinically utilized antibiotics. With a novel mechanism of action, pravibismane shuts down bacterial ATP production thereby halting global bacterial cellular metabolism.
Lead Product(s): Pravibismane
Therapeutic Area: Infections and Infectious Diseases Product Name: MBN-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: US Navy
Deal Size: $2.1 million Upfront Cash: Undisclosed
Deal Type: Funding June 07, 2022
Details:
MBN-101 (pravibismane) is first in a new class of anti-infective drugs structurally unrelated to other clinically utilized antibiotics. With a novel mechanism of action, pravibismane shuts down bacterial ATP production thereby halting global bacterial cellular metabolism.
Lead Product(s): Pravibismane
Therapeutic Area: Infections and Infectious Diseases Product Name: MBN-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
This new funding of up to $1.8 million will directly support IND-enabling toxicology studies of pravibismane and is in addition to $5.6 million previously awarded by the Foundation, for a combined total of up to $7.4 million.
Lead Product(s): Pravibismane
Therapeutic Area: Infections and Infectious Diseases Product Name: MBN-101
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cystic Fibrosis Foundation
Deal Size: $7.4 million Upfront Cash: Undisclosed
Deal Type: Funding February 22, 2021
Details:
Funding from the CF Foundation will enable Microbion to complete preclinical and Phase 1 studies of its antimicrobial drug pravibismane for the treatment of cystic fibrosis (CF)-related pulmonary infections.
Lead Product(s): Pravibismane
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CARB-X
Deal Size: $17.1 million Upfront Cash: Undisclosed
Deal Type: Funding May 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
